Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI filing briefs · archive

8-K filings in June 2023, explained

16 material Form 8-K filings that 14 companies we cover made with the SEC in June 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

1 of 16 briefs matches

newest first · times in ET
SCNIScinai Immunotherapeutics Ltd. Jun 8, 4:30 PM ET

Scinai Licenses IL-17 Antibody Technology from Max Planck, Gottingen Medical Center

Neutral product/contract Written later 1.01

On June 4, 2023, BiondVax Pharmaceuticals Ltd., which trades as SCNI, entered an exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) from Max-Planck-Innovation GmbH and University Medical Center Gottingen. The company agreed to issue 17,000 American Depository Shares to the counterparties and to owe milestone payments and royalties on net sales, and the license will terminate if an IND is not submitted by the stated deadlines.

  • 17,000 American Depository Shares to be issued to the counterparties within 45 days of June 4, 2023
  • Recipients agreed not to sell the ADSs until June 4, 2024
  • IND submission deadline of June 30, 2025, with a possible extension of 12 months per EUR 500,000 payment
  • License terminates prior to December 31, 2026 if the IND deadline is not met
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.